High-content imaging technology for the evaluation of drug-induced steatosis using a multiparametric cell-based assay.

Autores de IIS La Fe

• María Teresa Donato Martín

  Autor

• 

  Laia Tolosa Pardo

  Autor

• Nuria Jiménez Pous

  Autor

• José Vicente Castell Ripoll

  Autor

• María José Gómez-Lechón Moliner

  Autor

Grupos

• Hepatología experimental y Trasplante hepático

• Unidad Mixta de Investigación en Hepatología Experimental

Abstract

In the present study, we developed a cell-based protocol for the identification of drugs able to induce steatosis. The assay measures multiple markers of toxicity in a 96-well plate format using high-content screening (HCS) technology. After treating HepG2 cells with increasing concentrations of the tested compounds, toxicity parameters were analyzed using fluorescent probes: BODIPY493/503 (lipid content), 2',7'-dihydrodichlorofluorescein diacetate (reactive oxygen species [ROS] generation), tetramethyl rhodamine methyl ester (mitochondrial membrane potential), propidium iodide (cell viability), and Hoechst 33342 (nuclei staining). A total of 16 drugs previously reported to induce liver steatosis through different mechanisms (positive controls) and six nonsteatotic compounds (negative controls) were included in the study. All the steatosis-positive compounds significantly increased BODIPY493/503 fluorescence in HepG2 cells, whereas none of the negative controls induced lipid accumulation. In addition to effects on fat levels, increased ROS generation was produced by certain compounds, which could be indicative of increased risk of liver damage. Our results suggest that this in vitro approach is a simple, rapid, and sensitive screening tool for steatosis-inducing drugs. This conclusion should be confirmed by testing a larger number of steatosis-positive and -negative inducers.